Device Trial Radar · NCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
725
Planned (sponsor's estimate)
Start
May 8, 2026
Primary completion
May 15, 2032
Study completion Dec 30, 2037
Sponsor
- Lead sponsor
- Natera, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or continue hormone therapy with ongoing ctDNA surveillance. This study will compare outcomes to historical controls from the NataLEE trial to determine whether ctDNA-guided timing maintains efficacy while reducing unnecessary treatment. Participants will be followed for up to 9 years with regular blood draws, hormone therapy, imaging as needed, and quality-of-life assessments.
Conditions
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Receptors, Estrogen (for ER-positive Requirement)
Interventions
ctDNA-Guided Treatment StrategyDevice
Circulating tumor DNA testing using Signatera Genome assay is performed every 3 months for up to 4 years to guide timing of CDK4/6 inhibitor initiation. Participants with positive ctDNA results initiate CDK4/6 inhibitor therapy (ribociclib or abemaciclib) plus standard endocrine therapy for a minimum of 2 years. Participants with negative ctDNA results continue endocrine therapy alone with ongoing surveillance. CDK4/6 inhibitor selection and endocrine therapy regimen per the physician's choice following standard-of-care guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free SurvivalTime frame: From the date of surgery up to 9 years
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona · Not yet recruiting
Honor Health Research Institute
Scottsdale, Arizona · Not yet recruiting
University of Arizona Cancer Center
Tucson, Arizona · Not yet recruiting
47 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.